GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Interpace Biosciences Inc (STU:PF42) » Definitions » Additional Paid-In Capital

Interpace Biosciences (STU:PF42) Additional Paid-In Capital : €173.17 Mil(As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Interpace Biosciences Additional Paid-In Capital?


Interpace Biosciences's quarterly additional paid-in capital declined from Sep. 2023 (€176.17 Mil) to Dec. 2023 (€172.53 Mil) but then increased from Dec. 2023 (€172.53 Mil) to Mar. 2024 (€173.17 Mil).

Interpace Biosciences's annual additional paid-in capital increased from Dec. 2021 (€164.70 Mil) to Dec. 2022 (€177.02 Mil) but then declined from Dec. 2022 (€177.02 Mil) to Dec. 2023 (€172.53 Mil).

Interpace Biosciences Additional Paid-In Capital Historical Data

The historical data trend for Interpace Biosciences's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Interpace Biosciences Additional Paid-In Capital Chart

Interpace Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 164.26 151.58 164.70 177.02 172.53

Interpace Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 175.32 173.40 176.17 172.53 173.17

Interpace Biosciences Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Interpace Biosciences Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Interpace Biosciences's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Interpace Biosciences (STU:PF42) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Interpace Biosciences Inc (STU:PF42) » Definitions » Additional Paid-In Capital
Comparable Companies
XWEL LMDXF PRPO RNVA NDRA ISPC NSTM DIGP CNTG APDN TMO DHR A IDXX IQV XSWX:LONN MTD ICLR WAT ILMN
Traded in Other Exchanges
IDXG:USA
Address
300 Interpace Parkway, Morris Corporate Center 1, Building C, Parsippany, NJ, USA, 07054
Website
https://www.interpace.com
Interpace Biosciences Inc is engaged in the life sciences industry. It provides molecular diagnostics, bioinformatics, and pathology services for the evaluation of the risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The company develops and commercializes genomic tests and related first-line assays principally focused on the early detection of patients with indeterminate biopsies and at high risk of cancer using the latest technology. It operates under one segment which is the business of developing and selling diagnostic clinical services.

Interpace Biosciences (STU:PF42) Headlines

No Headlines